CogState releases details of UBC agreement
Tuesday, 29 July, 2008
Melbourne's CogState [ASX: CGS] has released the terms of its planned partnership with US pharmaceutical services company United BioSource Corporation [UBC], announced last week.
Under the arrangement, CogState and UBC will join forces to provide a comprehensive cognitive testing solution for use in clinical trials.
CogState markets six computerised diagnostic products to test cognitive function. It also has a therapeutic division with two compounds in early develop for Alzheimer's and Parkinson's diseases.
Under the agreement, UBC will buy a 15 per cent share in CogState, at a cost of around $800,000. UBC will also underwrite CogState's share rights issue.
Both companies will remain separate entities. In a statement to the stock exchange, CogState stressed that the arrangement will not necessitate any management changes or job losses.
NSW Govt delivers foot-and-mouth vaccine to protect livestock
A biodegradable vaccine to protect livestock from foot-and-mouth disease has been developed as...
Scientists optimise delivery of mRNA to target cells
A highly versatile new method captures and attaches antibodies to the surface of mRNA-loaded...
'Anti-reward' brain network helps explain cocaine addiction
A new study identifies a specific 'anti-reward' network deep in the brain that undergoes...
